Last reviewed · How we verify
BOL-303242-X
BOL-303242-X is a small molecule that targets the S1P1 receptor.
BOL-303242-X is a small molecule that targets the S1P1 receptor. Used for Non-infectious uveitis.
At a glance
| Generic name | BOL-303242-X |
|---|---|
| Also known as | Mapracorat |
| Sponsor | Bausch & Lomb Incorporated |
| Drug class | S1P receptor modulator |
| Target | S1P1 |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 2 |
Mechanism of action
By binding to the S1P1 receptor, BOL-303242-X modulates sphingosine-1-phosphate signaling, which plays a crucial role in lymphocyte trafficking and immune response. This mechanism is thought to contribute to its therapeutic effects in treating inflammatory conditions.
Approved indications
- Non-infectious uveitis
Common side effects
- Increased intraocular pressure
Key clinical trials
- Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome (PHASE2)
- Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery (PHASE2)
- Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery (PHASE3)
- Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BOL-303242-X CI brief — competitive landscape report
- BOL-303242-X updates RSS · CI watch RSS
- Bausch & Lomb Incorporated portfolio CI